David Sisam, DO
Endocrinology, Diabetes & Metabolism · Houma, LANPI 1124194840
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Merck at 45.1% of the total. Reporting peaked in 2019 at $6,886 and has fallen 84.0% since, to $1,103 in 2025.
Across 458 payments — averaging $29.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$6K
- Novo Nordisk$1K
- Amneal Pharmaceuticals LLC$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$986
- AbbVie$572
- IBSA Pharma Inc.$407
- plus $3K from 27 others
What the payments were for
- Speaking & faculty fees$5,46041%
- Travel & lodging$1751%
- Food & beverage$7,82058%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 35 | $6,066 |
| Novo Nordisk | 61 | $1,221 |
| Amneal Pharmaceuticals LLC | 72 | $1,080 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 70 | $986 |
| AbbVie | 36 | $572 |
| IBSA Pharma Inc. | 23 | $407 |
| AstraZeneca(2 entities) | 25 | $407 |
| Bayer | 17 | $365 |
| Antares Pharma, Inc. | 15 | $345 |
| Boehringer Ingelheim | 18 | $295 |
| Xeris Pharmaceuticals, Inc. | 11 | $228 |
| Lilly USA, LLC | 11 | $208 |
| Sanofi-aventis U.S. LLC | 13 | $208 |
| Amgen | 6 | $202 |
| Abbott | 10 | $201 |
| Halozyme Inc | 4 | $97 |
| Corcept Therapeutics | 4 | $74 |
| Dexcom, Inc. | 4 | $65 |
| Soleno Therapeutics, Inc. | 3 | $56 |
| Ultragenyx Pharmaceutical Inc. | 2 | $48 |
| Novartis | 3 | $42 |
| Ascendis Pharma Endocrinology Inc | 2 | $34 |
| Acella Pharmaceuticals, LLC | 2 | $31 |
| Clarus Therapeutics Inc. | 2 | $31 |
| Kyowa Kirin, Inc. | 1 | $29 |
| Nevro Corp. | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $23 |
| Tolmar, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Insulet Corporation | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$5,460
How this compares
$13,455 in reported general payments places this provider in the 75th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 133 | $142,102 |
| OzempicSemaglutide | 145 | $140,164 |
| JardianceEmpagliflozin | 162 | $136,002 |
| FarxigaDapagliflozin Propanediol | 102 | $81,432 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 79 | $59,496 |
| TrulicityDulaglutide | 46 | $59,084 |
| RybelsusSemaglutide | 44 | $52,720 |
| SynthroidLevothyroxine Sodium | 682 | $47,380 |
| CyclosetBromocriptine Mesylate | 32 | $45,085 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $25,267 |
| JanuviaSitagliptin Phosphate | 31 | $19,377 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $15,065 |
| TradjentaLinagliptin | 11 | $13,163 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $12,364 |
| InvokanaCanagliflozin | 13 | $7,943 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $208 | $201,186179 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,221 | $197,273204 claims |
| Boehringer IngelheimJardiance, Tradjenta | $295 | $149,165173 claims |
| AstraZenecaFarxiga | $407 | $81,432102 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $208 | $59,49679 claims |
| AbbVieSynthroid, Armour Thyroid | $572 | $53,201752 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCCycloset | $986 | $45,08532 claims |
| MerckJanuvia, Janumet | $6,066 | $31,74143 claims |
| Amneal Pharmaceuticals LLCUnithroid, Levothyroxine Sodium | $1,080 | $8,539448 claims |
| Johnson & JohnsonInvokana | $18 | $7,94313 claims |
| Antares Pharma, Inc.Xyosted | $345 | $7,00512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Houma
- Rachel Coleman-PierronHouma$2K
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.